The development of therapeutic antibodies targeting the GM-CSF receptor α-chain offers a valuable opportunity to test the importance of GM-CSF in JIA pathology, and early reports from rheumatoid arthritis studies are encouraging (19). Here, CSF2 is linked to rheumatoid arthritis.